Navigation Links
Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
Date:4/29/2008

- First 15 Patients Are Enrolled and Dosing With Bavituximab Plus Docetaxel

Combination Regimen is Underway -

TUSTIN, Calif., April 29 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection (HCV), today announced that it has completed enrollment in the first stage of its Phase II trial of bavituximab in combination with chemotherapy in patients with advanced breast cancer. The main objective of the safety and efficacy study is to assess the overall response rate to the combination of bavituximab with docetaxel, a chemotherapy drug commonly used to treat breast cancer.

"We are very pleased that patient enrollment in this trial has proceeded quickly, reflecting the enthusiasm and efficiency of our clinical colleagues in Europe and the level of patient interest in a potential new therapy for this difficult disease," said Steven W. King, president and CEO of Peregrine. "We look forward to providing an update on the trial as patients continue to be dosed in the study and tumor response data is generated."

As part of this trial's two-stage design, 15 patients with locally advanced or metastatic breast cancer have been enrolled initially. The primary objective of the multi-center, open-label study is to assess overall tumor response rate to the combination of bavituximab with docetaxel. The study may be expanded to include up to an additional 31 subjects if promising results are seen in the first 15 patients. Patients enrolled in the trial will remain in the study until disease progression.

Secondary objectives of the Phase II study include measur
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
2. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
3. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
4. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
5. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
6. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... HILDEN , Germany ... 2014 , ... Begleitdiagnostikums, das auf Basis genomischer Daten aus Plasmaproben ... mit nicht-kleinzelligem Lungenkrebs eingesetzt werden kann  ... zugelassenem  therascreen   EGFR Kit und soll auf Rotor-Gene ...
(Date:7/28/2014)... and LONDON , July ... Collaboration aims to create and commercialize companion diagnostic using ... of IRESSA  for non-small cell lung cancer patients  ... therascreen   EGFR test and is planned to run on Rotor-Gene Q, ... Project enabled by AstraZeneca master framework agreement adds ...
(Date:7/28/2014)... -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) ... 2014 financial results on Monday, August 4, 2014, after ... announcement, members of the management team will host a ... a general corporate update at 4:30 p.m. EDT (1:30 ... as follows: Monday, August 4 1:30 ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2
... 2007 - Cytogen,Corporation (NASDAQ: CYTO) reported updated ... evaluating QUADRAMET(R) (samarium Sm-153,lexidronam injection) in combination ... with relapsed,multiple myeloma. Data from 33 patients ... 1 Trial of Bortezomib (Vel) and Samarium,(Sam) ...
... achieved with VELCADE, lenalidomide,and dexamethasone , ,KOS, ... (Nasdaq: MLNM) today reported on the,presentation of ... based,therapies that showed consistently high survival and ... newly diagnosed,multiple myeloma (MM) patients. These data ...
Cached Medicine Technology:Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 2Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 3Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 4Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 6Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 7Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 8
(Date:7/28/2014)... Washington, DC (PRWEB) July 28, 2014 ... beyond, many are looking to private exchanges. “Private ... the August 6 webinar from Atlantic Information Services, will ... insurers’ private exchange strategies for the future. , Barbara ... from PwC with extensive experience in the private exchange ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 According to the ... is a comprehensive guide that will help people get rid ... readers all the necessary information about heartburn and acid reflux. ... truth about heartburn , and risk factors for reflux disease. ... will help people get rid of symptoms of reflux disease ...
(Date:7/28/2014)... 2014 Building a sense of neighborhood ... Where personal outdoor space is not possible, building ... fun and exercise outside is important. That’s why ... quality commercial playground equipment from APCPLAY. , Old Buckingham ... Virginia. It is an historic tourist location of one ...
(Date:7/28/2014)... Los Angeles, Calif., July 27, 2014 - (PRWEB) July 28, ... world title in 12 months by earning the Masters Champion ... July 20, proving that age is no obstacle for this ... and win at the event hosted by the International Pole ... 10 to 63, traveling from 30 countries, took part in ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Dr. Alan Xenakis, ... “DOC X MD Funny Feelings.” The new book, DOC ... Feelings in a unique story telling style with humor and ... and motivational. The reader will find answers to those age-old ... running water make people pee? Why do mosquitoes bite some ...
Breaking Medicine News(10 mins):Health News:Three PwC Consultants to Offer Insurers Successful Strategies for Private Exchanges 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 2Health News:Heartburn No More Pdf Review Exposes Jeff Martin's Guide For Treating Heartburn – Vkool.com 3Health News:Playground Creates Outdoor Fun for Community at Old Buckingham Station at Midlothian Village (VA) with APCPLAY© 2Health News:Inspiring Senior Athlete Lands Third World Title in One Year 2Health News:New Book by Alan P. Xenakis, MD Reveals Mind and Body Mysteries 2
... doing the rounds that global warming in the East ... A novel research by an international team places ... malaria’s spread, along with other factors like drug and ... University of Michigan theoretical ecologist Mercedes Pascual, has contributed ...
... with danger, is also the color of blood, signaling perpetuation ... of blood on a daily basis to cater to patients ... Sunderland have set the ball rolling, campaigning and urging people ... the run-up to Easter. ,Take the case of ...
... suggests that patients on the newer medications for diabetics ... spent between $920 and $1,760 less on annual total ... lead author and the Merrell Dow professor of pharmacy ... of medical records data on patients who took thiazolidinediones ...
... between widely used childhood medicines and the risk of developing ... allergies, expose the kids to pets and dirt early. The ... is known as the hygiene hypothesis. , It ... fields and farm animals, leaves people more susceptible to a ...
... review of several studies conducted on cancer-causing chemicals has ... babies as a consequence of exposure to organochlorines//. Pesticides ... such chemicals and may be passed on to humans ... it can be indirectly passed on to human beings ...
... cancer is one of the deadliest diseases in UK. Symptoms ... a need to rush to the loo//. ,Hence ... to increase awareness about prostate cancer. Prostate cancer kills 220 ... UK. ,Mr Campbell has won the support ...
Cached Medicine News:Health News:New Diabetic Drugs More Effective than Older Ones 2Health News:A Sneak Preview of Human’s Susceptibility to Auto Immune Disease, Allergy, Asthm 2Health News:Parents Concerned About Pesticide And Cancer Risk To Babies 2
The new Inferior Medial Orbital Rim Implant (IMORI) provides surgeons with an excellent alternative for patients with a deficient or recessed "tear trough" area often characterized as a look of fatig...
Flattened points in vertical plane, straight shafts, cross action, round handle....
Phaco chopper delicate rounded tip....
Karate chopper, spear shaped for ease of insertion into the nucleus....
Medicine Products: